Determinants of cancer drug pricing and how to overcome the cancer premium.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37059061.
- Also identified by DOI 10.1016/j.cell.2023.02.019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The high and increasing prices of cancer drugs are a public health challenge. To disrupt the cancer premium and improve patient access to cancer drugs, different action steps are indicated: more transparency on the price determination process and actual prices, value-based pricing, and "price with evidence development."
Medical subject headings
- Antineoplastic Agents
- Neoplasms